BACKGROUND: Renin-angiotensin system blockade reduces inflammation in several organ systems. Having found a fourfold increase in angiotensin II type Ia receptor expression in a dextran sodium sulfate colitis model, we targeted blockade with angiotensin II type Ia receptor antagonists to prevent colitis development. Because hypotension is a major complication of angiotensin II type Ia receptor antagonists use, we hypothesized that use of angiotensin II type Ia receptor antagonists compounds which lack cell membrane permeability, and thus enteric absorption, would allow for direct enteral delivery at far higher concentrations than would be tolerated systemically, yet retain efficacy. METHODS: Based on the structure of the angiotensin II type Ia receptor antagonist losartan, deschloro-losartan was synthesized, which has extremely poor cell membrane permeability. Angiotensin II type Ia receptor antagonist efficacy was evaluated by determining the ability to block NF-κB activation in vitro. Dextran sodium sulfate colitis was induced in mice and angiotensin II type Ia receptor antagonist efficacy delivered transanally was assessed. RESULTS: In vitro, deschloro-losartan demonstrated near equal angiotensin II type Ia receptor blockade compared to losartan as well as another angiotensin II type Ia receptor antagonist, candesartan. In the dextran sodium sulfate model, each compound significantly improved clinical and histologic scores and epithelial cell apoptosis. Abundance of TNF-α, IL-1β, and IL6 mRNA were significantly decreased with each compound. In vitro and in vivo intestinal drug absorption, as well as measures of blood pressure and mucosal and colonic blood flow, showed significantly lower uptake of deschloro-losartan compared to losartan and candesartan. CONCLUSIONS: This study demonstrated efficacy of high-dose angiotensin II type Ia receptor antagonists in this colitis model. We postulate that a specially designed angiotensin II type Ia receptor antagonist with poor oral absorption may have great potential as a new therapeutic agent for inflammatory bowel disease in the future.
BACKGROUND: Renin-angiotensin system blockade reduces inflammation in several organ systems. Having found a fourfold increase in angiotensin II type Ia receptor expression in a dextran sodium sulfatecolitis model, we targeted blockade with angiotensin II type Ia receptor antagonists to prevent colitis development. Because hypotension is a major complication of angiotensin II type Ia receptor antagonists use, we hypothesized that use of angiotensin II type Ia receptor antagonists compounds which lack cell membrane permeability, and thus enteric absorption, would allow for direct enteral delivery at far higher concentrations than would be tolerated systemically, yet retain efficacy. METHODS: Based on the structure of the angiotensin II type Ia receptor antagonist losartan, deschloro-losartan was synthesized, which has extremely poor cell membrane permeability. Angiotensin II type Ia receptor antagonist efficacy was evaluated by determining the ability to block NF-κB activation in vitro. Dextran sodium sulfatecolitis was induced in mice and angiotensin II type Ia receptor antagonist efficacy delivered transanally was assessed. RESULTS: In vitro, deschloro-losartan demonstrated near equal angiotensin II type Ia receptor blockade compared to losartan as well as another angiotensin II type Ia receptor antagonist, candesartan. In the dextran sodium sulfate model, each compound significantly improved clinical and histologic scores and epithelial cell apoptosis. Abundance of TNF-α, IL-1β, and IL6 mRNA were significantly decreased with each compound. In vitro and in vivo intestinal drug absorption, as well as measures of blood pressure and mucosal and colonic blood flow, showed significantly lower uptake of deschloro-losartan compared to losartan and candesartan. CONCLUSIONS: This study demonstrated efficacy of high-dose angiotensin II type Ia receptor antagonists in this colitis model. We postulate that a specially designed angiotensin II type Ia receptor antagonist with poor oral absorption may have great potential as a new therapeutic agent for inflammatory bowel disease in the future.
Authors: G E Hume; E V Fowler; D Lincoln; R Eri; D Templeton; T H Florin; J A Cavanaugh; G L Radford-Smith Journal: J Med Genet Date: 2006-10 Impact factor: 6.318
Authors: Linda M McAllister-Lucas; Jürgen Ruland; Katy Siu; Xiaohong Jin; Shufang Gu; David S L Kim; Peter Kuffa; Dawn Kohrt; Tak W Mak; Gabriel Nuñez; Peter C Lucas Journal: Proc Natl Acad Sci U S A Date: 2006-11-13 Impact factor: 11.205
Authors: Ariel U Spencer; Hua Yang; Emir Q Haxhija; Barbara E Wildhaber; Joel K Greenson; Daniel H Teitelbaum Journal: Dig Dis Sci Date: 2007-03-07 Impact factor: 3.199
Authors: Pablo Garrido-Gil; Ana I Rodriguez-Perez; Antonio Dominguez-Meijide; Maria J Guerra; Jose L Labandeira-Garcia Journal: Mol Neurobiol Date: 2018-02-05 Impact factor: 5.590
Authors: Manabu Okawada; Michael W Wilson; Scott D Larsen; Elke Lipka; John Hillfinger; Daniel H Teitelbaum Journal: Pediatr Surg Int Date: 2016-09-26 Impact factor: 1.827
Authors: Iñaki Robles-Vera; Marta Toral; Néstor de la Visitación; Manuel Sánchez; Manuel Gómez-Guzmán; Raquel Muñoz; Francesca Algieri; Teresa Vezza; Rosario Jiménez; Julio Gálvez; Miguel Romero; Juan Miguel Redondo; Juan Duarte Journal: Br J Pharmacol Date: 2020-02-03 Impact factor: 8.739
Authors: Jeffrey D Jacobs; Thomas Wagner; George Gulotta; Chuanhong Liao; Yan Chun Li; Marc Bissonnette; Joel Pekow Journal: Dig Dis Sci Date: 2019-02-06 Impact factor: 3.487